Your browser doesn't support javascript.
loading
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Cooper, Wendy A; Russell, Prudence A; Cherian, Maya; Duhig, Edwina E; Godbolt, David; Jessup, Peter J; Khoo, Christine; Leslie, Connull; Mahar, Annabelle; Moffat, David F; Sivasubramaniam, Vanathi; Faure, Celine; Reznichenko, Alena; Grattan, Amanda; Fox, Stephen B.
Afiliação
  • Cooper WA; Tissue Pathology and Diagnostic, Oncology, Royal Prince Alfred Hospital, New South Wales, Australia. Wendy.Cooper@sswahs.nsw.gov.au.
  • Russell PA; Sydney Medical School, The University of Sydney, Sydney, Australia.
  • Cherian M; School of Medicine, Western Sydney University, Sydney, Australia.
  • Duhig EE; Department of Anatomical Pathology, St Vincent's, Hospital and University of Melbourne, Victoria, Australia.
  • Godbolt D; The Canberra Hospital, Garran, Australian Capital Territory, Australia.
  • Jessup PJ; Sullivan Nicholaides Pathology, Tugun Lab, C/o John Flynn Hospital, Queensland, Australia.
  • Khoo C; Pathology Queensland-The Prince Charles Laboratory, The Prince Charles Hospital, Queensland, Australia.
  • Leslie C; Royal Hobart Hospital Pathology Service, Hobart, Tasmania, Australia.
  • Mahar A; Department of Pathology, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia.
  • Moffat DF; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Western Australia, Australia.
  • Sivasubramaniam V; Royal Prince Alfred Hospital, Department of Tissue Path and Diagnostic Oncology, Camperdown, New South Wales, Australia.
  • Faure C; SA Pathology, Department of Anatomical Pathology, FMC, Bedford Park, South Australia, Australia.
  • Reznichenko A; SydPath St Vincents Hospital, Department of Anatomical Pathology, Darlinghurst, New South Wales, Australia.
  • Grattan A; Mapi Group, Real World Evidence, Villette, Lyon, France.
  • Fox SB; MSD (Australia), Macquarie Park, New South Wales, Australia.
Clin Cancer Res ; 23(16): 4569-4577, 2017 Aug 15.
Article em En | MEDLINE | ID: mdl-28420726
ABSTRACT

Purpose:

Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are necessary to identify responders to anti-PD-1 therapy. We tested the reproducibility of the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) tissue samples by pathologists.Experimental

Design:

NSCLC samples were stained with PD-L1 22C3 pharmDx kit using the Dako Autostainer Link 48 Platform. Two sample sets of 60 samples each were designed to assess inter- and intraobserver reproducibility considering two cut points for positivity 1% or 50% of PD-L1 stained tumor cells. A randomization process was used to obtain equal distribution of PD-L1 positive and negative samples within each sample set. Ten pathologists were randomly assigned to two subgroups. Subgroup 1 analyzed all samples on two consecutive days. Subgroup 2 performed the same assessments, except they received a 1-hour training session prior to the second assessment.

Results:

For intraobserver reproducibility, the overall percent agreement (OPA) was 89.7% [95% confidence interval (CI), 85.7-92.6] for the 1% cut point and 91.3% (95% CI, 87.6-94.0) for the 50% cut point. For interobserver reproducibility, OPA was 84.2% (95% CI, 82.8-85.5) for the 1% cut point and 81.9% (95% CI, 80.4-83.3) for the 50% cut point, and Cohen's κ coefficients were 0.68 (95% CI, 0.65-0.71) and 0.58 (95% CI, 0.55-0.62), respectively. The training was found to have no or very little impact on intra- or interobserver reproducibility.

Conclusions:

Pathologists reported good reproducibility at both 1% and 50% cut points. More adapted training could potentially increase reliability, in particular for samples with PD-L1 proportion, scores around 50%. Clin Cancer Res; 23(16); 4569-77. ©2017 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Variações Dependentes do Observador / Carcinoma Pulmonar de Células não Pequenas / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Variações Dependentes do Observador / Carcinoma Pulmonar de Células não Pequenas / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália